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Thyroid hormone analogs with selective actions through specific thyroid hormone receptor (TR) sub-
typesareofgreat interest.Theymightofferthepossibilityofmimickingphysiologicalactionsofthyroid
hormone with receptor subtype or tissue specificity with therapeutic aims. They are also pharmaco-
logical tools to dissect biochemical pathwaysmediated by specific receptor subtypes, in a complemen-
taryway tomousegeneticmodifications. In thiswork,we studied the in vivoactivity indeveloping rats
of two thyroid hormone agonists, the TR-selective GC-24 and the TR-selective CO23. Our principal
goalwas to checkwhether these compoundswere active in the rat brain. Analog activitywas assessed
by measuring the expression of thyroid hormone target genes in liver, heart, and brain, after admin-
istration to hypothyroid rats. GC-24was very selective for TR and lacked activity on the brain. On the
other hand, CO23 was active in liver, heart, and brain on genes regulated by either TR or TR. This
compound, previously shown tobe TR-selective in tadpoles, displayedno selectivity in the rat in vivo.
(Endocrinology 152: 1136–1142, 2011)
The physiological actions of thyroid hormones aremediated in part by interaction of T3 with nuclear
receptors [thyroid hormone receptors (TRs)] and regu-
lation of gene expression (for a recent review, please see
Ref. 1). There are two receptor subtypes in mammals,
TR and TR, and three isoforms, TR1, TR1, and
TR2, encoded by two distinct genes, Thra and Thrb.
Results fromknockoutmice lacking either receptor sub-
type have shown overlapping as well as specific func-
tions in vivo (2–5). The different roles in vivo of TR1
and TR are mostly due to differences in cellular or
tissue expression, with some exceptions (6–8). In this
respect, TR1 is the predominant receptor subtype in
liver, whereas in the heart and brain, the predominant
receptor subtype is TR1, which accounts for up to
80–85% of total T3 binding (2, 9).
Selective targeting of TR has great therapeutic in-
terest, in view of the role that TR plays in lipid me-
tabolism (10, 11). TR-selective agonists are able to
reduce blood levels of cholesterol, triglycerides, and li-
poprotein(a) and may also reduce body weight (BW),
without affecting the heart. The metabolic actions of
several compounds, such as GC-1, GC-24, KB-141, and
KB-2115 (12–15), have been extensively studied, al-
though little attention has been paid to their effects on
the brain (8, 16–19). Given the involvement of TR1 in
behavior (20, 21), TR1 targeting in the brain might be
of value in the treatment of anxiety and other psychi-
atric disorders. T3 analogs able to be transported and
act on the brain would also be valuable agents in the
treatment of patients with monocarboxylate trans-
porter 8 (MCT8) mutations (22). The goal of this work
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was to examine whether the TR-selective T3 agonist
GC-24 (12, 19, 23) and the TR1-selective agonist,
CO23 (19, 24, 25), are active on T3 targets in the brain.
Materials and Methods
Wistar rats bred in our animal facilities were used. Animals
were under light- and temperature-controlled conditions
(12-h light, 12-h dark cycle and 22 2 C) and had free access
to food and water. Animal procedures were supervised by
institutional Ethic Committee, and in agreement with direc-
tives from the European Union. Euthyroid, hypothyroid, and
hypothyroid rat pups treatedwithT3 or the analogswere used.
Hypothyroidismwas induced by administering 0.02% 2-mer-
capto-1-methylimidazol (Sigma Chemical Co, St. Louis, MO)
and 1% KClO4 in the drinking water to the dams from ges-
tational d 9 until the end of the experiment on postnatal d
(P)16. T3 was administered to the hypothyroid pups at a daily
dose of 22.5 pmol/g of BW (15 ng/g) in PBS
containing 0.1% BSA. GC-24 and CO23 were
administered to the pups in the same solution
also as single daily ip injections at the doses
specified for each experiment. Treatments
were started on P10, and the last dose was ad-
ministered on P15. Twenty-four hours after the
last injection, the animals were anesthetized
and decapitated for PCR assays or perfused
with 4%paraformaldehyde in 0.1M phosphate
buffer for in situ hybridization.
RNApreparation and real-timePCRwasper-
formed as described (26), using TaqMan probes
(Applied Biosystems, Foster City, CA) for genes
previously shown to be sensitive to thyroid hor-
mones: type 1 deiodinase (Dio1, Rn00572183_m1),
glutathion-S-transferase (Gsta3, Rn00579867_m1),
sarcoplasmic reticulum ATPase or sarco/endoplas-
micreticulumcalciumtransportingATPase(Atp2a2,
Rn00568762_m1), myosin heavy chain  (Myh6,
Rn00568304_m1)andmyosinheavychain(Myh7,
Rn00568328_m1), hairless (Hr, Rn00577605_m1),
RevErbA (Nr1d1, Rn00595671_m1), neurotro-
phin 3 (Ntf3, Rn00579280_m1), reelin (Reln,
Rn00589609_m1), synaptotagmin 12 (Syt12,
Rn00593706_m1), RC3/neurogranin (Nrgn,
Rn00480741_m1), and ras homolog enriched
in striatum (Rasd2, Rn00592054_m1). TR
was also measured using a TaqMan probe (Thrb,
Rn00562044_m1),andTR1wasmeasuredusing
SYBRGreen quantitative PCR with the forward
primer 5AGCTGCTGATGAAGGTGACTGA3
and reverse primer 5TGAGGCTTTAGACT-
TCCTGATCCT3.
Total plasma cholesterol was measured us-
ing the Infinity Cholesterol kit supplied by
Thermo Electron (Thermo Fisher Scientific,
Auburn, AL). In situ mRNA hybridization
analysis for Nrgn, Rasd2 in the cerebrum, and
Hr in the cerebellum was performed using
methods previously described in detail (8). Pri-
mary neuronal cultures were established as
previously described (26).
Data were analyzed with the GraphPad
Prism 5 software (GraphPad, San Diego, CA).
For the comparisons between groups, we used
one-wayANOVAwith Tukeys test as post hoc
test. All results are expressed as mean  SEM.
Statistical comparisons shown in most panels
are made to the hypothyroid group, so as to
evaluate the effect of hypothyroidism vs. the
control and the effect of treatments vs. the hy-
FIG. 1. Effects of T3 and the TR synthetic agonists GC-24 and GC-1 on liver, heart,
striatum, and cerebellum. Black bars, Each compound was administered to hypothyroid rats
(H) as one daily injection of 22.5 pmol/g from P10 to P15. Open bar, Euthyroid animals. On
P16, several end points of thyroid hormone action were measured. Typical TR responses,
such as plasma cholesterol and liver Dio1 and Gsta3mRNAs, were sensitive to
hypothyroidism and drug administration. TR-mediated responses, such as heart Atp2a2,
Myh6, andMyh7, were sensitive to T3 but insensitive to GC-1 or GC-24 treatment. Thyroid
hormone-regulated striatal and cerebellar genes were insensitive to GC-24. Statistical
comparisons are made to the hypothyroid group, so as to evaluate the difference between
euthyroid (open bar) and hypothyroid animals and the effect of treatments vs. the untreated
hypothyroid animals. See Supplemental Table 1 for multiple cross comparisons. Eu,
Untreated euthyroid rats (n 5); H, untreated hypothyroid rats (n 5); T3, T3-treated H rats
(n 5); GC-24, GC-24-treated H rats (n 7); GC-1, GC-1-treated H rats (n 4). *, P
0.05; **, P 0.01; ***, P 0.001. ns, Not significant; FC, fold change.
Endocrinology, March 2011, 152(3):1136–1142 endo.endojournals.org 1137
pothyroid. Results on multiple comparisons of all groups
are provided in Supplemental Table 1, published on
The Endocrine Society’s Journals Online web site at
http://endo.endojournals.org.
Results
GC-24 is a TR-selective compound in vivo without
effects on the brain
T3 or GC-24 was administered to hypothyroid pups at
the dose of 22.5 pmol/g, and thyroid hormone responses
were studied in liver, heart, striatum, and cerebellum (Fig.
1). In agreement with the TR selectivity, GC-24 was ac-
tive in liver but not in heart. First, plasma cholesterol,
which in hypothyroid pups was elevated by 40% with
respect to controls, decreasedby45%after treatmentwith
T3 or GC-24. For comparison, we also tested the TR
selective compound GC-1 at the same molar dose. Treat-
ment of hypothyroid rats with this compound reduced
plasma cholesterol by 70%. As T3 target genes, we mea-
sured the expression of Dio1, an up-regulated gene (27),
and Gsta3, a down-regulated gene (28). Dio1 was de-
creased in hypothyroid animals to less than 10% of con-
trol values. It then increased after treatment of hypothy-
roid rats with T3 (12-fold), GC-24 (8-fold), or GC-1 (16-
fold). Conversely, Gsta3 was increased almost 2-fold in
untreated hypothyroid livers and was decreased by T3
(58%), GC-24 (25%), and GC-1 (68%). We found that
GC-1 was more potent than T3 or GC-24 on liver targets.
In the heart, the thyroid hormone responsive genes
Atp2a2 (29) andMyh6 (30) were decreased by hypothy-
roidism by 60 and 90%, respectively. T3 treatment of hy-
pothyroid rats induced these genes by 2- and 15-fold, re-
spectively, but neither GC-24 nor GC-1 were active.
Myh7, which increased 9-fold after hypothyroidism, de-
creased to euthyroid levels after T3, but GC-1 nor GC-24
were active. As for the brain, we measured the effects on
the striatum and the cerebellum. In the striatum, hypo-
thyroidism reduced the expression ofNrgn and Rasd2 by
75%, andT3 administration resulted in a 2.5-fold increase
of both genes, as shown before (8). Also, as reported pre-
viously (8), GC-1 increased Rasd2 expression but was
without effect on Nrgn. In contrast, GC-24 was without
effect on either gene. These results confirm previous find-
ings that regulation ofNrgnbyT3wasmediated byTR1,
whereas Rasd2 was also under the influence of TR (8).
Known target genes of thyroid hormone in the cerebel-
lum, such as ofNtf3 (31), Syt12,Hr (32), andNr1d1 (8),
were not influenced by treatment with GC-1 or GC-24.
The lack of effect of GC-24 in comparison with T3 was
also confirmed by in situ hybridization (Fig. 2) and by
analyzing its effect onmigration of cerebellar granule cells
(data not shown).
In view of the lack of effect of GC-24 on Rasd2, in
contrast to GC-1, we checked the effect of higher doses.
GC-24 was administered to the hypothyroid pups in in-
cremental doses of 22.5, 45, 90, and 225 pmol/g for 6 d
and compared with 22.5 pmol/g of T3. The results are
shown in Fig. 3. GC-24 induced liver responses, such as
cholesterol reduction, Dio1 up-regulation, and Gsta3
down-regulation at all the doses, whereas it had no effect
onNrgnandRasd2 in the striatumorHr in the cerebellum.
In addition, cerebellar Rln mRNA, which is down-regu-
lated by T3 through TR (8), was unaltered by GC-24
treatment (Supplemental Fig. 1).Despite the lack of action
in vivo, GC-24, as well as GC-1, was able to induce Hr in
cerebral cortex neurons in culture (Fig. 4).
CO23 acts through TR and TR in vivo and is
active in the brain
In preliminary experiments (data not shown), a dose of
CO23 of 22.5 pmol/g had no effect on plasma cholesterol,
FIG. 2. In situ hybridization for Nrgn, Rasd2 in the cerebrum, and Hr
in the cerebellum in euthyroid rats, hypothyroid rats (H), and
hypothyroid rats treated with one daily injection of 45 pmol/g BW T3
or GC-24 for 6 d. The fold change (FC) and statistical significance (P) of
differences respect to the hypothyroid sample are given after the
quantification of slices from three animals per group. Eu, Untreated
euthyroid; ns, not significant.
1138 Grijota-Martínez et al. In Vivo Activity of GC-24 and CO23 Endocrinology, March 2011, 152(3):1136–1142
liverDio1 andGsta3, heartMyh6,Myh7, andAtp2a2, or
cerebellumHr andNtf3. The same dose of T3 normalized
all these parameters, in a similar way as described in Fig.
1. The relative activity of CO23, compared with T3, was
then evaluated in cerebellar granule neurons in primary
cultures (Fig. 4). Addition of 10 nM T3 to the cultures
increasedHrmRNAalmostby20-foldandNtf3by3-fold.
CO23 was used at incremental doses of 10, 100, and 500
nM. Significant responses were obtained with the two
higher doses. The results suggested that CO23was at least
50 times less active than T3 on isolated neurons.
Based on the above data, we used CO23 for in vivo
experiments at doses of 0.04, 0.8, 2.5, and5.0 nmol/g, and
the results are shown in Fig. 5. After administration to
hypothyroid rats, cholesterol was not changed by the
lower dose, whereas the 0.8 nmol/g dose had a similar
effect as 22.5 pmol/g T3 (50% cholesterol reduction).
Higher CO23 doses were equally effective. T3 increased
Dio1 mRNA 10-fold after administra-
tion to hypothyroid rats. CO23 had no
effect at the lowest dose of 0.04 nmol/g
and increasedDio1mRNA5-, 10-, and
15-fold at the doses of 0.8, 2.5, and 5
nmol/g, respectively. Therefore, for
liver Dio1, a dose of 2.5 nmol/g of
CO23was equivalent to22.5pmol/gof
T3. The effect on Gsta3 was similar
than on cholesterol, with the dose of
0.8 nmol/g having a similar effect as
22.5 pmol T3 (65% Gsta3 mRNA re-
duction over hypothyroid levels).
In the heart, 2.5 nmol/g of CO23was
equivalent to 22.5 pmol/g of T3 on
Atp2a2 induction (1.8-fold in each
case), and the effect was still higher (2.4-
fold) with the highest dose. For the my-
osin heavy chains, 2.5 nmol/g of CO23
was also equivalent to 22.5 pmol/g T3 in
the induction of Myh6 (14-fold). T3
treatment decreased by 95% the ele-
vated levels ofMyh7mRNA of hypothyroid rats. Although
0.8 nmol/g of CO23 induced a 65% decreased, it required
the highest dose to elicit a similar effect than 22.5 pmol T3.
In the brain, the lowest effective dose of CO23 was 0.8
nmol for Syt12 induction (3-fold). ForNrgn,Rasd2,Ntf3,
and Nr1d1, the lowest dose that resulted in significant
inductionwas 2.5 nmol/g. The least sensitive genewasHr,
which required the highest dose of CO23 with about half
the effect of T3 (5.5- vs. 9.7-fold). In the cerebellum, Rln
was insensitive to CO23 (Supplemental Fig. 1).
Finally we considered the possibility that some of the
observations related to the effects of T3 analog adminis-
tration to hypothyroid pups was at least partially influ-
encedbyaltered expressionof theTRsbyhypothyroidism.
Therefore,wemeasured the relative amounts ofTR1and
TR mRNAs in the striatum of euthyroid and hypothy-
roid pups. Hypothyroidism increased TR1 mRNA by
48% (P  0.02) and decreased TR
mRNAby 25% (P 0.013) in relation
to the euthyroid values (Supplemental
Fig. 2).
Discussion
In this work, we compared the phar-
macological activity of two thyroid
hormone analogs, GC-24 and CO23,
previouslydescribedasbeingTR- and
TR1-selective compounds, respec-
tively (12, 23–25). Our primary inter-
FIG. 3. Effects of high doses of GC-24. Black bars, GC-24 was administered to hypothyroid
rats (H) as single daily injections for 6 d at the doses of 22.5, 45, 90, and 225 pmol/g BW.
These doses represent 1, 2, 4, and 10 the T3 dose used, 22.5 pmol/g BW. Although
GC-24 was active on the liver, there was no effect of on striatal or cerebellar genes. Statistical
comparisons are made to the hypothyroid group, so as to evaluate the difference between
euthyroid (open bar) and hypothyroid animals, and the effect of treatments vs. the
hypothyroid animals. See Supplemental Table 1 for multiple cross comparisons. Eu, Untreated
euthyroid rats; H, untreated hypothyroid rats. *, P  0.05; **, P  0.01; ***, P  0.001; n 
6 in all groups. ns, Not significant; FC, fold change.
FIG. 4. Effects of agonists of TR on primary cultures of cortical and cerebellar neurons.
Primary cultures were established from neonatal rat cortex (left panel) or cerebellum (right
panel) and incubated in the absence or presence of T3 1 (10 nM), GC-1, GC-24, or CO23 at
the concentrations indicated expressed as fold over the T3 concentration. *, P  0.05; **, P 
0.01; ***, P  0.001; n  6 in all groups. ns, Not significant; FC, fold change.
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estwas to analyze the effects of these compounds in the rat
brain, which is often neglected in studies on the biological
activity of thyroid hormone analogs.
As previously reported, GC-24was found to have TR
selectivity in vivo. Thyroid hormone-sensitive liver re-
sponses, such as plasma cholesterol, and expression of
Dio1 andGsta3 geneswere sensitive toGC-24. In contrast
to the liver, theheart genesAtp2a2,Myh6, andMyh7were
not sensitive toGC-24 orGC-1, as was
expected, because heart responses to
thyroid hormone are mediated in large
part by TR1 (33).
In contrast to the liver, GC-24 was
not active in the brain. We have previ-
ously shown that GC-1 has limited ac-
tivity in brain (8, 17, 18), especially on
genes that in the cerebellum are ex-
pressed in the granular cells, which ex-
press predominantly TR1. GC-24 was
also not active on cerebellar genes, but
GC-1 and GC-24 differed in the induc-
tion of striatalRasd2. In an earlier study
(8), we found that GC-1 was able to in-
duce Rasd2 in the striatum but not
Nrgn, even if these two genes are ex-
pressed in the same kind of cells, theme-
dium -aminobutyric acid-ergic in-
terneurons. We confirmed this result
and show here that in contrast to GC-1,
GC-24 was not active on Rasd2. In ad-
dition, GC-24 had no activity on cere-
bellar Rln, a gene also sensitive to GC-1
(8). The results indicate that GC-24 has
no activity in the brain, which is likely
due to restricted entry through the
blood-brain barrier. Another factor that
may contribute to the lack of activity of
TR-selective compounds in the brain is
the increase of the TR1/TR ratio that
occurs in hypothyroidism. An increase
of TR1 expression of 40% and de-
crease TR of 25%, as found in this
work, may facilitate TR1 responses,
especially in the setting of restricted
brain accumulation of the agonists.
As reportedpreviously byOcasio and
Scanlan (24), CO23 showed no prefer-
ence for TR subtype in a competitive
125I-T3 binding assay in vitro. Despite
this, it displayed TR-selective proper-
ties in cultured cells and in vivo. In cul-
tured cells, it had 5-fold higher activity
throughTR over TR in the activation
of a direct repeat 4 thyroid responsive element in U2OS and
HeLa cells (24). In vivo studies on the comparative actions
of T3, GC-1, and CO23 on metamorphosis showed that
CO23 had similar effects as T3 on hind limb growth but
required 7-fold higher concentrations (16, 24). CO23 was
much less active in tail, gills, andhead resorption.CO23had
also similar effects as T3 on cell proliferation in the ventric-
FIG. 5. Effect of CO23 on liver, heart, striatum, and cerebellum. Black bars, Hypothyroid rats
were given one daily dose of 22.5 pmol/g BW T3 for 6 d or incremental doses of CO23: 0.04,
0.8, 2.5, and 5.0 nmol/g BW (2, 40, 111, and 222, respectively, the molar dose of T3
used in the experiment). Statistical comparisons were made to the hypothyroid group, so as to
evaluate the difference between euthyroid (open bar) and hypothyroid animals and the effect
of treatments vs. the hypothyroid animals. See Supplemental Table 1 for multiple cross
comparisons. Eu, Untreated euthyroid rats; H, untreated hypothyroid rats; n  8 in all groups.
*, P  0.05; **, P  0.01; ***, P  0.001. ns, Not significant; FC, fold change.
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ular and subventricular zones during neurogenesis, whereas
GC-1 and GC-24 had no effect (16). It was also observed
that the combination of CO23 andGC-1was able tomimic
T3 action completely. These observations support the TR
selectivity of CO23.
Despite its TR subtype selectivity on tadpoles, when
administered to rats, CO23 was active in tissues express-
ing preferentially either TR1 or TR. For example,
CO23 was found to activate thyroid hormone-responsive
liver and heart genes in a similar way as T3, unlike the
TR-selective GC-1, which acts similarly to T3 in the liver
and lacks activity on the heart. These differences in TR
selectivity might be related to differences in tissue distri-
bution of the T3 analogs. For example, the accumulation
of GC-1 in liver is 17-fold of that in the heart, and this
contributes to the in vivo organ selectivity (10, 11). High
doses of CO23 needed to be used in vivo, due to the fact
that the relative potency of CO23, in comparisonwith T3,
was relatively low. In cultured cerebellar granular cells, it
was estimated that the potency of CO23 was more than
50-fold lower that of T3. In vivo, high doses 100- to 200-
fold of that of T3 had to be used. Therefore, it may be
argued that by using high doses of the agonist, we increase
the chance of having an effect in liver through activation
ofTR1, ifCO23accumulatespreferentially in this organ.
We have no data on tissue CO23 distribution. How-
ever, it seems unlikely that the effects of CO23 on plasma
cholesterol and liver Dio1 are due to preferential accu-
mulation of CO23 in the liver and subsequent activation
of TR1. The cholesterol response to thyroid hormone is
totally dependent on TR. TR knockout mice are resis-
tant to T3-induced reduction in cholesterol, a defect that
cannotbe rescuedbyoverexpressingTR1by6-fold in the
liver (34). On the other hand, Dio1 expression shows a
zonal distribution in the liver, with low mRNA concen-
tration around the periportal area and increasing toward
thepericentral area,where it reaches thehighest level. This
pattern of expression follows closely that of TR1 (35). In
addition, only extremely high doses of T3 administered to
TR-deficientmicewere able toweakly induceDio1 (36).
Therefore, we think that the liver responses to CO23 are
due to TR1 stimulation.
Taken together, the response of liver, heart, and brain
suggests that CO23 was similarly active on TR1 and
TR, but a subtle preference for TR1 cannot be dis-
carded. In fact, the lackof responseofRlnmaysuggest that
CO23 entry into the brain is not as efficient as in the liver,
precluding the activation of TR. Despite this, our results
indicate thatCO23was able to be transported through the
blood-brain barrier and to cross the neuronal cell mem-
brane. Although we did not identify the specific trans-
porter involved (37), it is unlikely that it uses the Mct8
transporter, which has extremely tight selectivity for T4
and T3. The reason for the apparent lack of receptor sub-
type selectivity of CO23 in rodents as compared with
metamorphosing tadpoles is unknownatpresent.The lack
of TR selectivity in mammalian tissues would make this
compound less interesting as a therapeutic agent. On the
other hand, its ability to cross the blood-brain barrier
would make it worth to investigate its capacity to act on
the brain in the absence of the specific T4 and T3 trans-
porter Mct8 (22).
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